The GLOBE Model: Assessing the Impact of Medicare’s New International Drug Pricing Framework

By Industry Analysis Desk | October 14, 2026

The landscape of American pharmaceutical pricing underwent a seismic shift on September 30, 2026, as the Centers for Medicare & Medicaid Services (CMS) finalized the "Global Benchmark for Efficient Drug Pricing Model," commonly referred to as the GLOBE Model. Published in the Federal Register on October 2, the rule introduces a mandatory Medicare Part B framework that ties drug rebates to prices paid in a basket of 19 high-income nations. While the final rule represents a scaled-back version of the original proposal, its implications for the global pharmaceutical industry, supply chain stability, and the future of healthcare innovation are profound.

1. Main Facts: The Anatomy of the GLOBE Model

At its core, the GLOBE Model is designed to curb the cost of Medicare Part B drugs by establishing a "Most Favored Nation" (MFN) style rebating mechanism. By anchoring domestic pricing to international benchmarks, the federal government seeks to reduce federal spending on high-cost therapeutics.

Key Operational Components:

• The Benchmark List: CMS has codified a list of 19 reference countries, including Australia, Japan, the United Kingdom, Germany, France, and Canada, among others.
• The Mechanism: The model requires manufacturers of selected drugs to provide rebates to Medicare when the U.S. price exceeds the international average, calculated through a specific methodology.
• Implementation Timeline: The rule takes effect on November 30, 2026, with a formal program start date of January 1, 2027.
• The "GENEROUS" Safety Valve: In a significant departure from the initial proposal, CMS has created a clear pathway for exemption. Manufacturers who opt into the voluntary Medicaid GENEROUS model—a parallel program focused on drug affordability—are effectively shielded from the mandatory mandates of the GLOBE Model.

According to current agency estimates, the combination of these exemptions, alongside the exclusion of orphan-only drugs, plasma-derived products, and specialized cell and gene therapies, will limit the direct impact of GLOBE to only four pharmaceutical manufacturers.

2. A Chronology of Policy and Pressure

The emergence of the GLOBE Model did not occur in a vacuum; it is the culmination of a multi-year effort by the administration to force industry compliance through a combination of "carrot and stick" tactics.

• November 2025: CMS introduces the GENEROUS model, a voluntary program designed to incentivize lower drug costs through collaborative agreements.
• December 2025: CMS releases the proposed rule for both the GLOBE Model (Part B) and the GUARD Model (Part D). These proposals acted as a "mandatory threat," creating an environment where pharmaceutical companies were under immense pressure to negotiate.
• Early 2026 – August 2026: A wave of high-level negotiations ensued. The industry saw a steady stream of manufacturers, ranging from large-cap entities to mid-sized biotech firms, entering into pricing arrangements with the administration. These agreements were widely perceived as a strategic move to secure immunity from the more punitive mandatory models.
• September 30, 2026: CMS releases the final GLOBE rule, formally codifying the exemption for GENEROUS participants.
• October 2026: The Pharmaceutical Research and Manufacturers of America (PhRMA) initiates litigation, filing a complaint challenging the legality and constitutionality of the model.

3. Supporting Data and Regulatory Infrastructure

Despite the narrow current scope of the GLOBE Model, industry experts warn that it represents a significant shift in infrastructure. CMS has effectively built a "ready-to-scale" machine that could, in future iterations, reach a much wider array of products.

The "Phase I" Strategy

CMS has explicitly described the current design as a "Phase I test." Under Section 1115A(c) of the Social Security Act, the Secretary of Health and Human Services possesses the authority to expand the duration and scope of a tested model, provided that statutory criteria are met. Specifically, if the model proves successful in reducing spending without compromising patient quality—a determination that would be certified by the CMS Chief Actuary—the agency could theoretically transition the GLOBE Model to a nationwide scale.

The Infrastructure of Reference Pricing

Even if the number of affected manufacturers is currently limited to four, the infrastructure established by the rule is durable:

1. Standardized Data Collection: A new, mandatory process for manufacturers to submit international net prices.
2. Benchmark Calculations: A dual-methodology approach to calculating rebates against the 19 identified international markets.
3. Rebate and Reconciliation: A cycle integrated into the existing Medicare inflation rebate program, creating a permanent administrative pipeline for international price tracking.

4. Official Responses and Legal Challenges

The pharmaceutical industry has responded with swift, categorical opposition. The lawsuit filed by PhRMA serves as the primary battleground for the future of the GLOBE Model.

The PhRMA Position

In its complaint filed in federal court, PhRMA challenges the model on three foundational grounds:

• Statutory Authority: PhRMA argues that the GLOBE Model does not constitute a valid "payment or service delivery model" under the existing Social Security Act. They contend that the administration is attempting to legislate through executive rulemaking rather than implementing a legitimate, small-scale test of care delivery.
• Constitutional Overreach: The suit asserts that the model infringes upon constitutional principles, effectively coercing manufacturers into agreements by threatening them with arbitrary mandatory rebates.
• Rewriting the Statute: The industry asserts that the CMS is attempting to unilaterally rewrite the Medicare Part B statute, a move that bypasses the constitutional role of Congress.

The CMS Perspective

CMS maintains that the GLOBE Model is a vital component of its broader effort to align U.S. drug prices with global standards. By focusing on international benchmarks, the agency claims it is fulfilling its mandate to ensure the long-term sustainability of the Medicare program while maintaining patient access to essential treatments.

5. Broader Implications: A "Global Populist" Shift

The GLOBE Model is more than a regulatory hurdle; it is a signal of a long-term, bipartisan trend toward "global populist" drug pricing policies. Whether or not the GLOBE Model survives its legal challenges, the underlying philosophy of international reference pricing has become a permanent fixture in the Washington policy conversation.

Impact on Global Dealmaking

The emergence of MFN-style policies has fundamentally changed the calculus for pharmaceutical licensing and global investment. Companies must now consider:

• Innovation Location: As price controls become a reality in the U.S. market, firms are re-evaluating where to conduct R&D and where to launch new products first.
• Licensing Risks: International licensing agreements are now being scrutinized for "price leakage," where a U.S. pricing decision could inadvertently trigger a downward adjustment in an international market, or vice versa.
• The GUARD Model Shadow: All eyes are currently on the Office of Management and Budget (OMB), which is reviewing the GUARD Model. If the GUARD final rule adopts a similarly aggressive approach to Part D pricing, the pressure on the industry will intensify, potentially leading to further consolidation of pricing strategies.

A New Era of "Voluntary" Compliance

The GLOBE Model’s reliance on the GENEROUS waiver highlights a sophisticated regulatory tactic: using the threat of mandatory, industry-wide disruption to force a voluntary, tiered entry into government-managed pricing. This "bargain" approach has become a hallmark of recent healthcare administration, creating a environment where "voluntary" participation is effectively a condition for market stability.

Conclusion: Preparing for the Future

For the broader pharmaceutical industry, the message is clear: even if a company is not currently in the "crosshairs" of the GLOBE Model, the regulatory climate has shifted. The creation of fixed international reference lists and the establishment of a robust, automated rebate reconciliation system mean that the infrastructure for global price anchoring is now firmly in place.

As the legal battle between the industry and the administration unfolds, companies must remain agile. The coming months will likely see further regulatory activity, particularly regarding the GUARD Model, which may provide additional clues as to how the government intends to navigate the legal and economic complexities of the international pricing landscape. For now, firms should treat the GLOBE Model not as an isolated incident, but as the first phase of a durable, long-term policy evolution that will necessitate a more globalized approach to drug pricing, legal strategy, and investor communications.

Disclaimer: This report is for informational purposes only and does not constitute legal or financial advice. Readers should consult with qualified legal counsel regarding the application of the GLOBE Model to their specific business circumstances.